Your session is about to expire
← Back to Search
Rectal Spacer Hydrogel for Prostate Cancer
Study Summary
This trial tests whether rectal spacer hydrogel can reduce radiation dose to the rectum in patients with prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My prostate cancer is high-risk with a Gleason score of 8 or higher, PSA over 20, or it has grown beyond the prostate.I have had surgery on my rectum, bowel, bladder, or prostate.My prostate cancer is confined to the prostate and my prostate is smaller than 150cc.My prostate is larger than 100 cc according to scans.I am able to care for myself and move around.I have had radiation therapy to my pelvic area before.My prostate cancer has spread beyond the prostate.I have had treatments for prostate cancer or am currently on experimental therapies.I am currently on hormone therapy for cancer.My prostate cancer was confirmed by a biopsy within the last year.I am older than 18 years.I have had cancer in my urinary or genital area before.My prostate cancer is at an intermediate risk stage.My doctor agrees I can have treatments including rectal spacer placement and specific radiotherapies.
- Group 1: Patients with prostate cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can patients join this trial at the current moment?
"Yes, this trial is recruiting patients as of now. The first posting was on 8/3/2021, with the most recent update happening on 1/25/2022 according to clinicaltrials.gov"
Does Stereotactic body radiation therapy carry any risks for patients?
"While there is some evidence of safety, as this is a Phase 2 trial, none of the data collected thus far supports efficacy. Therefore, our team has given Stereotactic body radiation therapy a score of 2."
How many people are receiving treatment as part of this experiment?
"That is correct, the online information on clinicaltrials.gov shows that this study needs more participants and is currently open for enrolment. This trial was first advertised on August 3rd 2021 and was updated most recently on January 25th 2022. So far, 57 patients have been recruited from 1 location."
Share this study with friends
Copy Link
Messenger